Australia's Memphasys soars on signing exclusive commercialisation agreement with NOVIVITAE

Memphasys

01/09/2026 04:58

** Shares of Australia's Memphasys MEM.AX rise as much as 20% to A$0.0060, headed for their biggest intraday pct gain since August 12
** Fertility technology co signs exclusive commercialisation agreement with Danish IVF and laboratory-technology distributor NOVIVITAE
** Adds, agreement to market and sell co's Felix Sytems, a bio-separation technology, in the Nordic region increasing co's presence in Europe
** Adds, agreement stipulates minimum purchase commitments worth €526,500 ($611,055.9) over a period of three years
** Stock down 21.4% YTD


($1 = 0.8616 euros)

 (Reporting by Shravya Marakini in Bengaluru)
 ((shravya.marakini@thomsonreuters.com;))